Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276744 · ClinicalTrials.gov registry record · Phase 2
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 249
- Enrollment target
NCT00276744 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 249 participants.
The verdict
NCT00276744, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 249 participants
- Enrollment target
Study Summary
RATIONALE: Treating tumor tissue in the laboratory with different drugs may help doctors find the best drug for treating individual patients with pancreatic cancer. PURPOSE: This phase II trial is studying an individualized drug treatment selection process, based on laboratory results, for treating patients with pancreatic cancer that can be removed by surgery.
Interventions
- DRUG Gemcitabine
- DRUG docetaxel
- DRUG Erlotinib
- BIOLOGICAL cetuximab
- DRUG capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2005-10 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00276744
The ClinicalTrials.gov registry entry for NCT00276744 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gemcitabine is the first listed.
NCT00276744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00276744 about?
NCT00276744 is a clinical study titled "Individualized Drug Treatment for Treating Patients With Pancreatic Cancer". RATIONALE: Treating tumor tissue in the laboratory with different drugs may help doctors find the best drug for treating individual patients with pancreatic cancer. PURPOSE: This phase II trial is studying an individualized drug treatment selection process, based on laboratory results, for treating...
What is the current status of trial NCT00276744?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 249 participants. The study started on 2005-10. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00276744?
The interventions under investigation include: Gemcitabine (DRUG), docetaxel (DRUG), Erlotinib (DRUG), cetuximab (BIOLOGICAL), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00276744?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.